Skip to navigation Skip to content

Participe en una prueba clínica

Sin la participación de personas con esclerosis múltiple, sería imposible desarrollar nuevos y mejores tratamientos, y otras intervenciones.

Share

Nos esforzamos por traducir cada vez más contenido al español, pero algunos de los enlaces incluidos aquí van a páginas en inglés. Si usa el traductor de su navegador, tenga en cuenta que es posible que la traducción no sea exacta.

Pruebas clínicas cercanas

¿Tiene interés en las pruebas clínicas? Simplemente busque por estado, tipo de esclerosis múltiple o palabra clave, y vea qué está sucediendo en su zona.

v

  1. Clinical Trial: Tai Chi and Mindfulness Training

    Investigators are recruiting people with all subtypes of MS (participants need to capable of standing and moving unaided for a minimum of 15 minutes at a time) to investigate the impact of mindfulness training on balance and wellbeing in individuals with MS. This is a communit...

    Obtener detalles

  2. Clinical Trial: Computerized Cognitive Training

    The purpose of this study is to evaluate two computerized brain training tools, which include light physical activity, to see if they can help improve cognitive functions, such as memory and attention, for people with MS. Participants would complete a set of tests (physical an...

    Obtener detalles

  3. Clinical Trial: Cognitive Processing Speed Changes in Relapsing MS Treated With Ozanimod (RPC-1063)

    A study to determine if oral ozanimod can affect cognitive processing speed in people with relapsing MS. All subjects will receive orally administered ozanimod HCl 1 mg.  Please note: In response to the recent developments of the COVID-19 pandemic, sites are implementing me...

    Obtener detalles

  4. Research Study: Fatigue

    Please note: This is not a clinical trial of an intervention, but rather a research study.  The purpose of this study is to systematically evaluate the relationship between fatigue severity, autonomic (involuntary) symptom burden, and autonomic physiological markers in MS p...

    Obtener detalles

  5. Clinical Trial: Cognitive Processing Speed Changes in Relapsing MS Treated With Ozanimod (RPC-1063)

    A study to determine if oral ozanimod can affect cognitive processing speed in people with relapsing MS. All subjects will receive orally administered ozanimod HCl 1 mg.  Please note: In response to the recent developments of the COVID-19 pandemic, sites are implementing me...

    Obtener detalles

  6. Clinical Trial: Ofatumumab

    A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient- reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy. FDA Approved medication (Brand na...

    Obtener detalles

  7. Clinical Trial: Cognitive Processing Speed Changes in Relapsing MS Treated With Ozanimod (RPC-1063)

    A study to determine if oral ozanimod can affect cognitive processing speed in people with relapsing MS. All subjects will receive orally administered ozanimod HCl 1 mg. 

    Obtener detalles

  8. Research Study: Physiologic dysfunction in MS-related Fatigue

    This research study is designed to assess whether physiologic dysfunction contributes to fatigue in people with MS. This connection will help guide routine neurological treatment fatigue in MS in the future.  Physiologic testing includes measurement of a person’s pupil functi...

    Obtener detalles

  9. Clinical Trial: Ocrelizumab

    This is a double blind, multicenter study to evaluate the effectiveness, safety and pharmacokinetics (how the drug moves within the body) of a higher dose of ocrelizumab taken via intravenous infusion every 24 weeks in people with relapsing MS, in comparison to the approved 60...

    Obtener detalles

  10. Clinical Trial: Ozanimod for Cognitive Function

    This is a multicenter, single-arm, open-label study to describe the change from baseline in cognitive processing speed in subjects with relapsing multiple sclerosis (RMS) treated with ozanimod HCl 1 mg at 3 years. All enrolled subjects will receive orally administered ozanimod...

    Obtener detalles

    11.  |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10  >  >| 

Share

© 2024 La Sociedad Nacional de Esclerosis Múltiple es una entidad sin fines de lucro de tipo 501(c)3 y exenta de impuestos. Su número de identificación (EIN por su sigla en inglés) es 13-5661935.